Quote:

---

Well, in the case of a cancer that has developed high levels of resistance to Keytruda, the addition of leronlimab would likely disable those biochemical mechanisms which the cancer tumor developed in order to outsmart the PD1 blockade.

---

Most of that drug resistance comes from mutated tumor cell DNA so leronlimab would not help resistance to Keytruda. Leronlimab knocks down PD-L1 the ligand for PD-1 effectively doing the same thing as Keytruda. The difference being that PD-L1 not being part of the tumor cell, DNA alterations would have no effect on leronlimab's mechanism of action regarding PD-1/PD-L1 and therefore no resistance developing.